Multi-color laser technology – redefined

Featuring a proprietary dual-mode laser cavity, Integre Pro™ delivers uniform energy distribution across the full spot diameter, eliminating hotspots and achieving optimal, homogenous burns. It’s a key feature that means you can achieve consistent, predictable treatment outcomes across a broad range of pathologies.

Related treatments

Related conditions

Related products

Main Image Landing Integre Pro
Uniform energy distribution
Uniform energy distribution

Continuous feedback for excellent results

Integre Pro™ delivers real-time, active light feedback that continuously monitors and adjusts power output, combined with high-grade laser components. The result is consistent, reliable performance in the treatment of retinal disease.

See more, see better

The purpose-built Integre Pro™ slit lamp, which channels the laser directly through the slit lamp optics for better visualization and optimal illumination, is optimized for use in the posterior segment. Featuring a 10-degree stereoscopic angle, it provides enhanced depth perception and a wider peripheral view, as well as high-contrast imaging and optimal illumination of the fundus.

High precision performance for retinal disease treatment 

Integre Pro's high power, yellow-red configuration redefines multi-color laser technology, offering the full treatment spectrum of a traditional three-color photocoagulator. By combining high-precision optics matched to optimized laser performance, it’s one of the leading systems for retinal disease diagnosis and treatment.

Wavelength Clinical Characteristics



Hotspots Integre Pro
A choice of Yellow-Red and Green-Red multi-wavelength configurations provides the flexibility to address a number of different pathologies.
Hotspots Integre Pro2
All controls — spot size, energy, shot duration and micromanipulator — are conveniently located, right at your fingertips.

Contact us

*Not for complaints or regulatory bodies. View our Privacy Policy

Integre Pro™ has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) (510k) Market release for the indications of Retinal Photocoagulation, Laser Trabeculoplasty and Laser Iridotomy. Ellex does not accept any responsibility for use of the system outside of these indications.

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More

QUANTEL MEDICAL COMPLETES ACQUISITION OF ELLEX

Quantel Medical has completed its acquisition of Ellex, including the company’s laser and ultrasound technology solutions (with the exception of 2RT® and iTrack®), via the financial holding company Lumibird Medical.

The coming together of these two companies—both renowned in the field of ophthalmology—represents a real milestone in their history. Quantel Medical and Ellex have a shared heritage in the development of cutting-edge technologies for the diagnosis and treatment of the leading causes of blindness worldwide: glaucoma, cataracts, AMD and diabetic retinopathy.